AE-RA-ILD N = 58 | AE-IPF N = 96 | P-value | |
---|---|---|---|
Age, yearsa | 73 (68–80) | 74 (69–79) | 0.8244 |
Sex, male | 35 (60.3) | 81 (84.4) | 0.0011 |
Smoking, evera | 39 (67.2) | 80 (83.3) | 0.0286 |
Baseline %FVCb | 81.7 (66.2–90.6) | 69 (54.2–84.4) | 0.0059 |
Baseline %DLCOb, c | 59.9 (47.1–75.4) | 58.5 (43.0–78.5) | 0.9939 |
P/F at AE, Torra | 220 (163–285) | 223 (163–276) | 0.7883 |
C-reactive protein, mg/dLa | 9.4 (5.7–14.9) | 11.4 (8.3–17.2) | 0.3654 |
Rheumatoid factor, U/mLa | 116 (37–322) | – | – |
ACPA, positiveb, d | 41 (89.1) | – | – |
KL-6, U/mLa | 1042 (739–1559) | 1530 (973–2456) | 0.0013 |
Baseline HRCT patternb | < 0.0001 | ||
UIP | 34 (58.6) | 85 (88.5) | |
Probable UIP | 10 (17.2) | 11 (11.5) | |
Indeterminate for UIP | 3 (5.2) | 0 (0) | |
Alternative | 11 (19.0) | 0 (0) | |
Infection-triggered AEe | 5 (8.6) | 12 (12.5) | 0.5983 |
Treatment for AE | |||
Methylprednisolone pulse | 58 (100) | 96 (100) | 1.0000 |
Prednisolone | 58 (100) | 96 (100) | 1.0000 |
Immunosuppressant | 31 (53.5) | 34 (35.4) | 0.0304 |
Intravenous cyclophosphamide | 19 (32.8) | 32 (33.3) | 1.0000 |
Calcineurin inhibitor | 13 (22.4) | 2 (2.1) | < 0.0001 |
Post-AE observation period, day | 121 (22–755) | 236 (28–477) | 0.8741 |
Mortality within 90 days after AE onset | 28 (48.3) | 34 (35.4) | 0.1292 |
Mortality during study period | 43 (74.1) | 82 (85.4) | 0.0925 |
Respiratory condition-related mortality | 37 (63.8) | 71 (74.0) | 0.2058 |